|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBOOKCENTRAL_on1260346176 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
210717s2016 xx o ||| 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d SFB
|d LOA
|d S2H
|d DST
|d SGP
|d REDDC
|d OCLCF
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCQ
|d DXU
|d OCLCL
|
| 066 |
|
|
|c (S
|
| 020 |
|
|
|a 9781681082950
|
| 020 |
|
|
|a 1681082950
|
| 035 |
|
|
|a (OCoLC)1260346176
|
| 050 |
|
4 |
|a RC280.N43
|b .F766 2016
|
| 082 |
0 |
4 |
|a 616.9948
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Atta-ur-Rahman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research - CNS and Neurological Disorders
|h [electronic resource].
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (0 p.).
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - CNS and Neurological Disorders Ser.
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 505 |
0 |
|
|a Intro -- CONTENTS -- PREFACE -- List of Contributors -- Multiple Sclerosis Drug Therapy: From the Classical Pharmaceutical Down to Cellular and Molecular Approach -- MULTIPLE SCLEROSIS -- Epidemiology, Environmental Agents and Genetics -- Pathogenesis -- Animal Models -- Different Immune System Players on the MS Stage -- T-cells -- B-cells -- Other Immune System Cells and the Innate Immune Response -- Histopathology -- Active Lesions -- Chronic Plaques -- Remyelinated Plaques -- Clinical Features and Diagnostic Criteria -- DISEASE-MODIFYING DRUGS -- Steroids -- Injectable Drugs
|
| 505 |
8 |
|
|a Beta-Interferons -- Glatiramer Acetate -- Oral Drugs -- Teriflunomide -- Dimethyl Fumarate (DMF, BG-12) -- Fingolimod (FTY720) -- Conventional Immunosuppressants -- Cyclophosphamide -- Azathioprine -- Mitoxantrone -- Laquinimod -- Methotrexate -- Biologics (Monoclonal Antibodies) -- Natalizumab -- Alemtuzumab (Campath-1H) -- RECENT EMERGING BIOLOGICAL AND EXPERIMENTAL THERAPEUTICAL APPROACHES -- B-Cells -- Rituximab -- Ocrelizumab and Ofatumumab -- MEDI-551 -- Mast Cells -- Masitinib mesylate -- Cytokines and Chemokines -- Daclizumab -- Tabalumab (LY2127399) -- MOR103 -- Secukinumab
|
| 505 |
8 |
|
|a I.5.2. PSEN1/PSEN2 -- I.5.3. APOE -- I.5.4 . APOJ/CLU -- I.5.5. The Role of Genetic Testing in Clinical Care -- II. THE ROLE OF BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIALS ASSESSMENT -- II.1. Biochemical Markers -- II.1.1. Cerebrospinal Fluid Biomarkers -- II.1.2. Blood Biomarkers -- II.2. Imaging-based Biomarkers -- II.2.1. Structural Magnetic Resonance Imaging -- II.2.2. Diffusion Tensor Imaging -- II.2.3. Functional Magnetic Resonance Imaging -- II.2.4. Proton Magnetic Resonance Spectroscopy -- II.2.5. Fluorodeoxyglucose-Positron Emission Tomography
|
| 505 |
8 |
|
|a II.2.6. Amyloid-Positron Emission Tomography -- II.3. The Continuum of AD: Diagnosis and Prognosis -- II.4. Regulatory Framework -- III. PROSPECTIVE THERAPIES -- III.1. Non-immunologic Therapies -- III.1.1. Clinical Trials -- III.1.2. Preclinical Studies -- III.2. Immunotherapy -- III.2.1. Active Immunotherapy -- III.2.2. Passive Immunotherapy -- CONCLUSION AND FUTURE PERSPECTIVES -- CONFLICT OF INTEREST -- FUNDING -- ACKNOWLEDGMENTS -- REFERENCES -- At the Crossroad between Neuronal Hyperexcitability and Neuroinflammation: New Therapeutic Opportunities for Alzheimer's Disease? -- INTRODUCTION
|
| 500 |
|
|
|a 1. BACKGROUND ON AD.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Central nervous system.
|
| 650 |
|
2 |
|a Central Nervous System
|
| 650 |
|
6 |
|a Système nerveux central.
|
| 650 |
|
7 |
|a Central nervous system
|2 fast
|
| 758 |
|
|
|i has work:
|a CNS and neurological disorders Volume 2 Frontiers in clinical drug research (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFBwc8f6WpYTjF8Kw8qDC3
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman
|t Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 4
|d Sharjah : Bentham Science Publishers,c2016
|z 9781681082967
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - CNS and Neurological Disorders Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=6675052
|z Texto completo
|
| 880 |
8 |
|
|6 505-00
|a Tolerogenic Vaccines for MS -- Stem Cells -- Haematopoietic Stem Cells (HSCs) -- Mesenchymal Stem Cells (MSCs) -- Helminths -- Vitamin D -- Remyelination Strategies in MS -- BIIB033 -- rHIgM22 -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Prospective Therapies for Alzheimer Disease: Biomarkers, Clinical Trials and Preclinical Research -- I. INTRODUCTION -- I.1. Background -- I.2. Alzheimer's Disease and the Need for New Drugs -- I.3. The Amyloid Cascade Hypothesis (ACH) -- I.4. Correlation among Aβ and other AD Hallmarks -- I.5. Genetics of AD -- I.5.1. APP
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL6675052
|
| 994 |
|
|
|a 92
|b IZTAP
|
